BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 7594922)

  • 41. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen.
    Jamet P; Ji B
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):622. PubMed ID: 7868967
    [No Abstract]   [Full Text] [Related]  

  • 42. A case of lepromatous leprosy with multiple relapses.
    Hulmani M; Marne RB; Dandakeri S
    Lepr Rev; 2009 Jun; 80(2):210-4. PubMed ID: 19743626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines.
    Balagon MF; Cellona RV; Cruz Ed; Burgos JA; Abalos RM; Walsh GP; Saunderson PR; Walsh DS
    Am J Trop Med Hyg; 2009 Nov; 81(5):895-9. PubMed ID: 19861628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
    Kaur I; Dogra S; Kumar B; Radotra BD
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
    Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Newer drugs in leprosy.
    Grosset JH
    Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of response to WHO/MDT; a case report.
    Habtemariam H; Guebre-Xabier M
    Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):632-4. PubMed ID: 8151198
    [No Abstract]   [Full Text] [Related]  

  • 48. The response to chemotherapy of serum Mycobacterium leprae-specific antigen in multibacillary leprosy patients.
    Roche PW; Britton WJ; Neupane KD; Failbus SS; Cho SN; Theuvenet WJ
    Am J Trop Med Hyg; 1991 Jun; 44(6):702-8. PubMed ID: 1858971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of pefloxacin in the treatment of lepromatous leprosy.
    N'Deli L; Guelpa-Lauras CC; Perani EG; Grosset JH
    Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):12-8. PubMed ID: 2181041
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Drug resistance of Mycobacterium leprae].
    Pattyn SR
    Acta Leprol; 1986; 4(3):279-87. PubMed ID: 3551466
    [No Abstract]   [Full Text] [Related]  

  • 51. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.
    Boerrigter G; Pönnighaus JM; Fine PE; Wilson RJ
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):255-61. PubMed ID: 2071983
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Borderline Lepromatous Leprosy with Type 1 (Reversal) Reactions in a Chinese Man.
    Fu X; Liu H; Zhang F
    Am J Trop Med Hyg; 2015 Aug; 93(2):207-209. PubMed ID: 26251526
    [No Abstract]   [Full Text] [Related]  

  • 53. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
    Dhople AM; Lamoureux LC; Gardner GD
    Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
    Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relapse of leprosy after multidrug therapy.
    Dasananjali K
    J Med Assoc Thai; 1996 Oct; 79(10):635-9. PubMed ID: 8996998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determination of in vivo and in vitro drug effects of mycobacteria from the mass spectrometric analysis of single organisms.
    Haas M; Lindner B; Dietz M; Tebebe YB; Seydel U
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):262-70. PubMed ID: 2071984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy.
    Pattyn S; Grillone S
    Lepr Rev; 2002 Sep; 73(3):245-7. PubMed ID: 12449889
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent trends in chemotherapy of leprosy.
    Parikh DA; Maniar JK; Parikh AC; Ganapati R
    J Assoc Physicians India; 1985 Sep; 33(9):593-5. PubMed ID: 3912375
    [No Abstract]   [Full Text] [Related]  

  • 59. Silent iritis in treated bacillary negative leprosy.
    Thompson K; Job CK
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):306-10. PubMed ID: 8862265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined regimens of one year duration in the treatment of multibacillary leprosy--I. Combined regimens with rifampicin administered during one year.
    Pattyn SR; Bourland J; Grillone S; Groenen G; Ghys P
    Lepr Rev; 1989 Jun; 60(2):109-17. PubMed ID: 2671559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.